Infections associated with prosthetic heart valves, vascular prostheses, and cardiac pacemakers and defibrillators;Infecciones asociadas a las válvulas protésicas cardíacas, las prótesis vasculares y los dispositivos de electroestimulación cardíacos

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue 10, 2008, Pages 647-664

  Almirante, Benito ^a   Miró, José M ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cardiovascular device infections; Defibrillator endocarditis; Infection of intravascular prostheses; Pacemaker endocarditis; Prosthetic valve endocarditis

Indexed keywords

AMPHOTERICIN B; AMPICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; CIPROFLOXACIN; CLOXACILLIN; FLUCYTOSINE; GENTAMICIN; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

BLOOD CULTURE; BLOOD VESSEL PROSTHESIS; DEFIBRILLATOR; HEART VALVE PROSTHESIS; HUMAN; INFECTION; PACEMAKER; REVIEW; STAPHYLOCOCCUS;

ANTIBIOTIC PROPHYLAXIS; ANTICOAGULANTS; BLOOD VESSEL PROSTHESIS; COMBINED MODALITY THERAPY; DEFIBRILLATORS, IMPLANTABLE; DEVICE REMOVAL; ENDOCARDITIS; HEART VALVE PROSTHESIS; HUMANS; INCIDENCE; PACEMAKER, ARTIFICIAL; PREMEDICATION; PROSTHESIS IMPLANTATION; PROSTHESIS-RELATED INFECTIONS; REOPERATION; RISK FACTORS;

EID: 58149506108     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/s0213-005x(08)75281-9     Document Type: Review

References (155)

1. Karchmer AW, Longworth DL. Infections of intracardiac devices. Infect Dis Clin N Am. 2002;16:477-505.
2. Baddour LM, Bettmann MA, Bolger AF, Epstein AE, Ferrieri P, Gerber MA, et al. Nonvalvular cardiovascular device-related infections. Circulation. 2003;108:2015-31.
3. Gandelman G, Frishman WH, Wiese C, Green-Gastwirth V, Hong S, Aronow WS, et al. Intravascular device infections: epidemiology, diagnosis, and management. Cardiol Rev. 2007;15:13-23.
4. Sampedro MF, Patel R. Infections associated with long-term prosthetic devices. Infect Dis Clin North Am. 2007;21:785-819.
5. Baddour LM, Wilson WR. Infections of prosthetic valves and other cardiovascular devices. En: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 1002-44.
6. Igual A, Saura E. Cirugía cardiovascular en España en el año 2005. Registro de intervenciones de la Sociedad Española de Cirugía Torácica y Cardiovascular. Cir Cardiov. 2007;14:227-41.
7. a ed. Madrid: Ediciones Elsevier España; 2008. p. 638-52.
8. Habib G, Thuny F, Avierinos JF. Prosthetic valve endocarditis: current approach and therapeutic options. Prog Cardiovasc Dis. 2008;50:274-81.
9. Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG, Bayer AS, et al. Clinical Presentation, Etiology and Outcome of Infective Endocarditis in the 21st Century: The International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2008 (en prensa).
10. Calderwood SB, Swinski LA, Waternaux CM, Karchmer AW, Buckley MJ. Risk factors for the development of prosthetic valve endocarditis. Circulation. 1985;72:31-7.
11. Glower DD, Landolfo KP, Cheruvu S, Cen YY, Harrison JK, Bashore TM, et al. Determinants of 15-year outcome with 1,119 standard Carpentier-Edwards porcine valves. Ann Thorac Surg. 1998;66:S44-8.
12. Ivert TSA, Dismukes WE, Cobbs CG, Blackstone EH, Kirklin JW, Bergdahl LAL. Prosthetic valve endocarditis. Circulation. 1984;69:223-32.
13. Agnihotri AK, McGiffin DC, Galbraith AJ, O'Brien MF. Surgery for acquired heart disease. J Thorac Cardiovasc Surg. 1995;110:1708-24.
14. Arvay A, Lengyel M. Incidence and risk factors of prosthetic valve endocarditis. Eur J Cardio-Thorac. 1988;2:340-6.
15. Rutledge R, Kim J, Applebaum RE. Actuarial analysis of the risk of prosthetic valve endocarditis in 1,598 patients with mechanical and bioprosthetic valves. Arch Surg. 1985;120:469-72.
16. Bloomfield P, Wheatley DJ, Prescott RJ. Twelve-year comparison of a Bjork-Shiley mechanical heart valve with procine bioprostheses. N Engl J Med. 1991;324:573-9.
17. Grover FL, Cohen DJ, Oprian C, Henderson WG, Sethi G, Hammermeister KE. Determinants of the occurrence of and survival from prosthetic valve endocarditis. J Thorac Cardiovasc Surg. 1994;108:207-14.
18. Hammermeister KE, Sethi GK, Henderson WG. A comparison of outcomes eleven years after heart valve replacement with a mechanical valve or prosthesis. N Engl J Med. 1993;328:1289-96.
19. López J, Revilla A, Vilacosta I, Villacorta E, González-Juanatey C, Gómez I, et al. Definition, clinical profile, microbiological spectrum, and prognostic factors of early-onset prosthetic valve endocarditis. Eur Heart J. 2007;28:760-5.
20. Wilson WR, Jaumin PM, Danielson GK, Giuliani ER, Washington JA II, Geraci JE. Prosthetic valve endocarditis. Ann Intern Med. 1975;82:751-6.
21. Masur H, Johnson WD Jr. Prosthetic valve endocarditis. J Thorac Cardiovasc Surg. 1980;80:31-7.
22. Dismukes WE, Karchmer AW, Buckley MJ, Austen WG, Swartz MN. Prosthetic valve endocarditis: analysis of 38 cases. Circulation. 1973;48:365-77.
23. Wang A, Athan E, Pappas PA, Fowler VG Jr, Olaison L, Paré C, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA. 2007;297:1354-61.
24. Hoen B, Alla F, Selton-Suty C, Béguinot I, Bouvet A, Briançon S, et al. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA. 2002;288:75-81.
25. Tornos P, Iung B, Permanyer-Miralda G, Baron G, Delahaye F, Gohlke-Bärwolf C, et al. Infective endocarditis in Europe: lessons from the Euro heart survey. Heart. 2005;91:571-5.
26. Vila J, Soriano A, Mensa J. Molecular basis of microbial adherence to prosthetic materials. Role of biofilms in prosthesis-associated infection. Enferm Infecc Microbiol Clin. 2008;26:48-54.
27. Otto M. Staphylococcal biofilms. Curr Top Microbiol Immunol. 2008;322:207-28.
28. Boyce JM, Potter-Bynoe G, Opal SM, Dziobek L, Medeiros AA. A common-source outbreak of Staphylococcus epidermidis infections among patients undergoing cardiac surgery. J Infect Dis. 1990;161:493-9.
29. Van den Broek PJ, Lampe AS, Berbee GAM, Thompson J, Mouton RP. Epidemic of prosthetic valve endocarditis caused by Staphylococcus epidermidis. BMJ. 1985;291:949-50.
30. Lytle BW, Priest BP, Taylor PC, Loop FD, Sapp SK, Stewart RW, et al. Surgery for acquired heart disease: surgical treatment of prosthetic valve endocarditis. J Thorac Cardiovasc Surg. 1996;111:198-210.
31. Fang G, Keys TF, Gentry LO, Harris AA, Rivera N, Getz K, et al. Prosthetic valve endocarditis resulting from nosocomial bacteremia: a prospective, multicenter study. Ann Int Med. 1993;119:560-7.
32. Nasser RM, Melgar GR, Longworth DL, Gordon SM. Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia. Am J Med. 1997;103:25-32.
33. Rivas P, Alonso J, Moya J, de Górgolas M, Martinell J, Fernández Guerrero ML. The impact of hospital-acquired infections on the microbial etiology and prognosis of late-onset prosthetic valve endocarditis. Chest. 2005;128:764-71.
34. Fernández-Hidalgo N, Almirante B, Tornos P, Pigrau C, Sambola A, Igual A, Pahissa A. Contemporary epidemiology and prognosis of health care-associated infective endocarditis. Clin Infect Dis. 2008;47:1287-97.
35. a ed. Madrid: Ediciones Elsevier España; 2004. p. 635-48.
36. Chu V, Miro JM, Hoen B, Cabell CH, Pappas PA, Jones P, et al. Coagulase-negative staphylococcal prosthetic valve endocarditis: a contemporary update based on the International Collaboration on Endocarditis - Prospective Cohort Study. Heart. 2008 Oct 24. [Epub ahead of print]
37. Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Int Med. 1983;98:447-55.
38. Murray BE, Karchmer AW, Moellering RC Jr. Diphtheroid prosthetic valve endocarditis: a study of clinical features and infecting organisms. Am J Med. 1980;69:838-48.
39. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis. 2001;32:50-62.
40. Gilbert HM, Peters ED, Lang SJ, Hartman BJ. Successful treatment of fungal prosthetic valve endocarditis: case report and review. Clin Infect Dis. 1996;22:348-54.
41. Melgar GR, Nasser RM, Gordon SM, Lytle BW, Keys TF, Longworth DL. Fungal prosthetic valve endocarditis in 16 patients. An 11 year experience in a tertiary care hospital. Medicine (Baltimore). 1997;76:94-103.
42. Raoult D, Tissot-Dupont H, Foucault C, Gouvernet J, Fournier PE, Bernit E, et al. Q fever 1985-1998: clinical and epidemiologic features of 1,383 infections. Medicine (Baltimore). 2000;79:109-23.
43. Anderson DJ, Bulkley BH, Hutchins GM. A clinicopathologic study of prosthetic valve endocarditis in 22 patients: morphologic basis for diagnosis and therapy. Am Heart J. 1977;94:325-32.
44. Arnett EN, Roberts WC. Prosthetic valve endocarditis: clinicopathologic analysis of 22 necropsy patients with comparison of observations in 74 necropsy patients with active infective endocarditis involving natural left-sided cardiac valves. Am J Cardiol. 1976;38:281-91.
45. Ismail MB, Hannachi N, Abid F, Kaabar Z, Rouge JF. Prosthetic valve endocarditis: a survey. Br Heart J. 1987;58:72-7.
46. Richardson JV, Karp RB, Kirklin JW, Dismukes WE. Treatment of infective endocarditis: a 10-year comparative analysis. Circulation. 1978;58:589-97.
47. Rose AG. Prosthetic valve endocarditis: a clinicopathological study of 31 cases. S Afr Med J. 1986;69:441-5.
48. Madison J, Wang K, Gobel FL. Prosthetic aortic valve endocarditis. Circulation. 1975;51:940-9.
49. Fernicola DJ, Roberts WC. Frequency of ring abscess and cuspal infection in active infective endocarditis involving bioprosthetic valves. Am J Cardiol. 1993;72:314-23.
50. Baumgartner WA, Miller DC, Reitz BA, Oyer PE, Jamieson SW, Stinson EB, Shumway NE. Surgical treatment of prosthetic valve endocarditis. Ann Thorac Surg. 1983;35:87-102.
51. Calderwood SB, Swinski LA, Karchmer AW, Waternaux CM, Buckley MJ. Prosthetic valve endocarditis: analysis of factors affecting outcome of therapy. J Thorac Cardiovasc Surg. 1986;92:776-83.
52. Horstkotte D, Körfer R, Loogen F, Rosin H, Bircks W. Prosthetic valve endocarditis: clinical findings and management. Eur Heart J. 1984;5 Suppl C:117-22.
53. Tornos P, Sanz E, Permanyer-Miralda G, Almirante B, Planes AM, Soler-Soler J. Late prosthetic valve endocarditis: immediate and long-term prognosis. Chest. 1992;101:37-41.
54. Archer GL, Karchmer AW, Vishniavsky N, Johnston JL. Plasmid-pattern analysis for the differentiation of infecting from noninfecting Staphylococcus epidermidis. J Infect Dis. 1984;149:913-20.
55. Van Wijngaerden E, PeetermansWE,Van Lierde S, Van Eldere J. Polyclonal staphylococcus endocarditis. Clin Infect Dis. 1997;25:69-71.
56. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111:e394-434.
57. Khandheria BK. Transesophageal echocardiography in the evaluation of prosthetic valves. Am J Cardiac Imag. 1995;9:106-14.
58. Stewart WJ, Shan K. The diagnosis of prosthetic valve endocarditis by echocardiography. Sem Thorac Cardiovasc Surg. 1995;7:7-12.
59. Daniel WG, Mugge A, Grote J, Hausmann D, Nikutta P, Laas J, et al. Comparison of transthoracic and transesophageal echocardiography for detection of abnormalities of prosthetic and bioprosthetic valves in the mitral and aortic positions. Am J Cardiol. 1993;71:210-5.
60. Morguet AJ, Werner GS, Andreas S, Kreuzer H. Diagnostic value of transesophageal compared with transthoracic echocardiography in suspected prosthetic valve endocarditis. Herz. 1995;20:390-8.
61. Vered Z, Mossinson D, Peleg E, Kaplinsky E, Motro M, Beker B. Echocardiographic assessment of prosthetic valve endocarditis. Eur Heart J. 1995;16 Suppl B:63-7.
62. Daniel WG, Mugge A, Martin RP, Lindert O, Hausmann D, Nonnast-Daniel B, et al. Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N Engl J Med. 1991;324:795-800.
63. Sochowski RA, Chan KL. Implication of negative results on a monoplane transesophageal echocardiographic study in patients with suspected infective endocarditis. J Am Coll Cardiol. 1993;21:216-21.
64. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am J Med. 1994;96:200-9.
65. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633-8.
66. John MVD, Hibberd PL, Karchmer AW, Sleeper LA, Calderwood SB. Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis. 1998;26:1302-9.
67. Nettles RE, McCarty DE, Corey RG, Li J, Sexton DJ. An evaluation of the Duke criteria in 25 pathologically confirmed cases of prosthetic valve endocarditis. Clin Infect Dis. 1997;25:1401-3.
68. Pérez-Vázquez A, Fariñas MC, García-Palomo JD, Bernal JM, Revuelta JM, González-Macías J. Evaluation of the Duke criteria in 93 episodes of prosthetic valve endocarditis: could sensitivity be improved? Arch Intern Med. 2000;160:1185-91.
69. Roe MT, Abramson MA, Li J, Heinle SK, Kisslo J, Corey GR, Sexton DJ. Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocarditis by the Duke criteria. Am Heart J. 2000;139:945-51.
70. Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, Pavie A, et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J. 2004;25:267-76.
71. Archer GL, Johnston JL, Vazquez GJ, Haywood Iii HB. Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies. Rev Infect Dis. 1983;5 Suppl 3:S538-42.
72. Chuard C, Herrmann M, Vaudaux P, Waldvogel FA, Lew DP. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobialcombinations. Antimicrob Agents Chemother. 1991;35:2611-6.
73. Kobasa WD, Kaye KL, Shapiro T, Kaye D. Therapy for experimental endocarditis due to Staphylococcus epidermidis. Rev Infect Dis. 1983;5 Suppl 3:S533-54.
74. Lucet JC, Herrmann M, Rohner P, Auckenthaler R, Waldvogel FA, Lew DP. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1990;34:2312-7.
75. Rouse MS, Wilcox RM, Henry NK, Steckelberg JM, Wilson WR. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother. 1990;34:273-6.
76. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193-200.
77. Fowler VG, Jr., Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-65.
78. Marco F, de la Mària CG, Armero Y, Amat E, Soy D, Moreno A, et al. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52:2538-43.
79. Gudiol F, Aguado JM, Pascual A, Pujol M, Almirante B, Miró JM, et al. Documento de Consenso sobre Tratamiento de la Bacteriemia y la Endocarditis causada por Staphylococcus aureus resistente a la meticilina. Enferm Infecc Microbiol Clin. 2008 (en prensa).
80. Miro JM, Del Rio A, Moreno A, Peña C, Cervera C, Soy D, et al. Efficacy and safety of fosfomycin (f) plus imipenem (i) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) native valve endocarditis (NVE): preliminary results of a clinical trial. 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008). Washington, DC; October 25-28, 2008. L-1523
81. Gavalda J, Len O, Miro JM, Muñoz P, Montejo M, Alarcon A, et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med. 2007;146:574-9.
82. Nguyen MH, Nguyen ML, Yu VL, McMahon D, Keys TF, Amidi M. Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature. Clin Infect Dis. 1996;22:262-7.
83. Habib G, Tribouilloy C, Thuny F, Giorgi R, Brahim A, Amazouz M, et al. Prosthetic valve endocarditis: who needs surgery? A multicentre study of 104 cases. Heart. 2005;91:954-9.
84. Wang A, Pappas P, Anstrom KJ, Abrutyn E, Fowler VG Jr, Hoen B, et al. The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort. Am Heart J. 2005;150:1086-91.
85. Karchmer AW, Dismukes WE, Buckley MJ, Austen WG. Late prosthetic valve endocarditis: clinical features influencing therapy. Am J Med. 1978;64:199-206.
86. Yu VL, Fang GD, Keys TF, Harris AA, Gentry LO, Fuchs PC, et al. Prosthetic valve endocarditis: superiority of surgical valve replacement versus medical therapy only. Ann Thorac Surg. 1994;58:1073-7.
87. Saffle JR, Gardner P, Schoenbaum SC, Wild W. Prosthetic valve endocarditis: the case for prompt valve replacement. J Thorac Cardiovasc Surg. 1977;73:416-20.
88. Tornos P, Almirante B, Olona M, Permanyer G, González T, Carballo J, et al. Clinical outcome and long-term prognosis of late prosthetic valve endocarditis: a 20-year experience. Clin Infect Dis. 1997;24:381-6.
89. Horstkotte D, Bircks W, Loogen F. Infective endocarditis of native and prosthetic valves-the case for prompt surgical intervention? A retrospective analysis of factors affecting survival. Z Kardiol. 1986;75 Suppl 2:168-82.
90. Reinhartz O, Herrmann M, Redling F, Zerkowski HR. Timing of surgery in patients with acute infective endocarditis. J Cardiovasc Surg. 1996;37:397-400.
91. Boyd AD, Spencer FC, Isom OW, Cunningham JN, Reed GE, Acinapura AJ, Tice DA. Infective endocarditis: an analysis of 54 surgically treated patients. J Thorac Cardiovasc Surg. 1977;73:23-30.
92. Morris AJ, Drinkovic' D, Pottumarthy S, MacCulloch D, Kerr AR, West T. Bacteriological outcome after valve surgery for active infective endocarditis: implications for duration of treatment after surgery. Clin Infect Dis. 2005;41:187-94.
93. Anguera I, Miró JM, Cabell CH, Abrutyn E, Fowler VG Jr, Hoen B, et al. Clinical characteristics and outcome of aortic endocarditis with periannular abscess in the International Collaboration on Endocarditis Merged Database. Am J Cardiol. 2005;96:976-81.
94. Anguera I, Miró JM, Vilacosta I, Almirante B, Anguita M, Munoz P, et al. Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur Heart J. 2005;26(3):288-97.
95. d'Udekem Y, David TE, Feindel CM, Armstrong S, Sun Z. Long-term results of operation for paravalvular abscess. Ann Thorac Surg. 1996;62:48-53.
96. Jault F, Gandjbakhch I, Chastre JC, Levasseur JP, Bors V, Gibert C, et al. Prosthetic valve endocarditis with ring abscesses: surgical management and long-term results. J Thorac Cardiovasc Surg. 1993;105:1106-13.
97. Anwar H, Strap JL, Costerton JW. Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy. Antimicrob Agents Chemother. 1992;36:1347-51.
98. Wolff M, Witchitz S, Chastang C, Regnier B, Vachon F. Prosthetic valve endocarditis in the ICU: prognostic factors of overall survival in a series of 122 cases and consequences for treatment decision. Chest. 1995;108 688-94.
99. Roder BL, Wandall DA, Espersen F, Frimodt-Moller N, Skinhoj P, Rosdahl VT. A study of 47 bacteremic Staphylococcus aureus endocarditis cases: 23 with native valves treated surgically and 24 with prosthetic valves. Scand Cardiovasc J. 1997;31:305-9.
100. Sett SS, Hudon MPJ, Jamieson WRE, Chow AW. Prosthetic valve endocarditis: experience with porcine bioprostheses. J Thorac Cardiovasc Surg. 1993;105:428-34.
101. Chirouze C, Cabell CH, Fowler VG Jr, Khayat N, Olaison L, Miró JM, et al. Prognostic factors in 61 cases of Staphylococcus aureus prosthetic valve infective endocarditis from the International Collaboration on Endocarditis merged database. Clin Infect Dis. 2004;38:1323-7.
102. Aragam JR, Weyman AE. Echocardiographic findings in infective endocarditis. En: Weyman AE, editor. Principles and practice of echocardiography. Philadelphia (PA): Lea & Febiger; 1994. p. 1178-97.
103. David TE. The surgical treatment of patients with prosthetic valve endocarditis. Sem Thorac Cardiovasc Surg. 1995;7:47-53.
104. Dossche KM, Defauw JJ, Ernst SM, Craenen TW, DeJongh BM, de la Riviere AB. Allograft aortic root replacement in prosthetic aortic valve endocarditis: a review of 32 patients. Ann Thorac Surg. 1997;63:1644-9.
105. Glazier JJ, Verwilghen J, Donaldson RM, Ross DN. Treatment of complicated prosthetic aortic valve endocarditis with annular abscess formation by homograft aortic root replacement. J Am Coll Cardiol. 1991;17:1177-82.
106. Pansini S, di Summa M, Patane F, Forsennati PG, Serra M, Del Ponte S. Risk of recurrence after reoperation for prosthetic valve endocarditis. J Heart Valve Dis. 1997;6:84-7.
107. Davenport J, Hart RG. Prosthetic valve endocarditis (1976-1987): antibiotics, anticoagulation, and stroke. Stroke. 1990;21:993-9.
108. Delahaye JP, Poncet PH, Malquarti V, Beaune J, Gare JP, Mann JM. Cerebrovascular accidents in infective endocarditis: role of anticoagulation. Eur Heart J. 1990;11:1074-8.
109. Horskotte D, Piper C, Niehues R, Wiemer M, Schultheiss HP. Late prosthetic valve endocarditis. Eur Heart J. 1995;16 Suppl B:39-47.
110. Leport C, Vilde JL, Bricaire F, Cohen A, Pangon B, Gaudebout C, et al. Fifty cases of late prosthetic valve endocarditis: improvement in prognosis over a 15 year period. Br Heart J. 1987;58:66-71.
111. Wilson WR, Geraci JE, Danielson GK, Thompson RL, Spittell JA Jr, Washington JR 2nd, et al. Anticoagulant therapy and central nervous system complications in patients with prosthetic valve endocarditis. Circulation. 1978;57:1004-7.
112. Wilson W, Taubert K, Gewitz M, Lockhart P, Baddour L, Levison M, et al. Prevention of Infective Endocarditis. Guidelines from the American Herat Association. A Guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116:1736-54.
113. Duval X, Leport C. Prophylaxis of infective endocarditis: current tendencies, continuing controversies. Lancet Infect Dis. 2008;8:225-32.
114. Kieffer E, Sabatier J, Plissonnier D, Knosalla C. Prosthetic graft infection after descending thoracic/ thoracoabdominal aortic aneurysmectomy: management with in situ arterial allografts. J Vasc Surg. 2001;33:671-8.
115. Swain TW 3rd, Calligaro KD, Dougherty MD. Management of infected aortic prosthetic grafts. Vasc Endovascular Surg. 2004;38:75-82.
116. Vogel TR, Symons R, Flum DR. The incidence and factors associated with graft infection after aortic aneurysm repair. J Vasc Surg. 2008;47:264-9.
117. Seeger JM, Pretus HA, Welborn MB, Ozaki CK, Flynn TC, Huber TS. Long-term outcome after treatment of aortic graft infection with staged extra-anatomic bypass grafting and aortic graft removal. J Vasc Surg. 2000;32:451-9; discussion 460-1.
118. Bunt TJ. Vascular graft infections: an update. Cardiovasc Surg. 2001;9:225-33.
119. Chiesa R, Astore D, Frigerio S, Garriboli L, Piccolo G, Castellano R, et al. Vascular prosthetic graft infection: epidemiology, bacteriology, pathogenesis and treatment. Acta Chir Belg. 2002;102:238-47.
120. Bandyk DF, Esses GE. Prosthetic graft infection. Surg Clin North Am. 1994;74:571-90.
121. Almirante B, Giménez M. Infecciones de válvulas protésicas, marcapasos y prótesis vasculares. En: Ausina V, Moreno S, directores. Tratado SEIMC de Enfermedades Infecciosas y Microbiología Clínica. Madrid: Editorial Médica Panamericana; 2006. p. 1315-25.
122. Sierra J, Kalangos A, Faidutti B, Christenson JT. Aorto-enteric fistula is a serious complication to aortic surgery. Modern trends in diagnosis and therapy. Cardiovasc Surg. 2003;11:185-8.
123. Valentine RJ. Diagnosis and management of aortic graft infection. Semin Vasc Surg. 2001;14: 292-301.
124. Goëau-Brissonnière OA, Coggia M. Arterial prosthetic infections. En: Waldvogel F, Bisno AL, editors. Infections associated with indwelling devices. 3rd ed. Washington, DC: American Society for Microbiology; 2000. p. 127-44.
125. Liberatore M, Iurilli AP, Ponzo F, Prosperi D, Santini C, Baiocchi P, et al. Clinical usefulness of technetium-99m-HMPAO-labeled leukocyte scan in prosthetic vascular graft infection. J Nucl Med. 1998;39:875-9.
126. Seeger JM. Management of patients with prosthetic vascular graft infection. Am Surg. 2000;66:166-77.
127. O'Connor S, Andrew P, Batt M, Becquemin JP. A systematic review and meta-analysis of treatments for aortic graft infection. J Vasc Surg. 2006;44:38-45.
128. Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR, and Society of Thoracic Surgeons. The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part I: Duration. Ann Thorac Surg. 2006;81:397-404.
129. Engelman R, Shahian D, Shemin R, Guy TS, Bratzler D, Edwards F, et al. The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. Ann Thorac Surg. 2007;83:1569-76.
130. Disponible en: www.marcapasossec.org (acceso 10/3/2008).
131. Peinado R, Torrecilla EG, Ormaetxe J, Álvarez M, y Grupo de Trabajo de Desfibrilador Implantable. Registro Español de Desfibrilador Automático Implantable. III Informe Oficial del Grupo de Trabajo de Desfibrilador Automático Implantable de la Sociedad Española de Cardiología (2006). Rev Esp Cardiol. 2007;60:1290-301.
132. Harcombe AA, Newell SA, Ludman PF, Wistow TE, Sharples LD, Schofield PM, et al. Late complications following permanent pacemaker implantation or elective unit replacement. Heart. 1998;80:240-4.
133. Trappe HJ, Pfitzner P, Klein H, Wenzlaff P. Infections after cardioverter-defibrillator implantation: observations in 335 patients over 10 years. Br Heart J. 1995;73:20-4.
134. Arber N, Pras E, Copperman Y, Schapiro JM, Meiner V, Lossos IS, et al. Pacemaker endocarditis. Report of 44 cases and review of the literature. Medicine (Baltimore). 1994;73:299-305.
135. Duval X, Selton-Suty C, Alla F, Salvador-Mazenq M, Bernard Y, Weber M, et al. Endocarditis in patients with a permanent pacemaker: a 1-year epidemiological survey on infective endocarditis due to valvular and/or pacemaker infection. Clin Infect Dis. 2004;39:68-74.
136. Uslan DZ, Sohail MR, St Sauver JL, Friedman PA, Hayes DL, Stoner SM, et al. Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. Arch Intern Med. 2007;167:669-75.
137. Da Costa A, Lelièvre H, Kirkorian G, Célard M, Chevalier P, Vandenesch F, et al. Role of the preaxillary flora in pacemaker infections: a prospective study. Circulation. 1998;97:1791-5.
138. Spittell PC, Hayes DL. Venous complications after insertion of a transvenous pacemaker. Mayo Clin Proc. 1992;67:258-65.
139. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, et al. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis. 2007;45:166-73.
140. Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N, et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation. 2007;116:1349-55.
141. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, et al. Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator infection. Mayo Clin Proc. 2008;83:46-53.
142. Lai KK, Fontecchio SA. Infections associated with implantable cardioverter defibrillators placed transvenously and via thoracotomies: epidemiology, infection control, and management. Clin Infect Dis. 1998;27:265-9.
143. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol. 2007;49:1851-9.
144. Chua JD, Wilkoff BL, Lee I, Juratli N, Longworth DL, Gordon SM. Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Ann Intern Med. 2000;133:604-8.
145. Klug D, Lacroix D, Savoye C, Goullard L, Grandmougin D, Hennequin JL, et al. Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. Circulation. 1997;95:2098-107.
146. Chamis AL, Peterson GE, Cabell CH, Corey GR, Sorrentino RA, Greenfield RA, et al. Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation. 2001;104:1029-33.
147. Cacoub P, Leprince P, Nataf P, Hausfater P, Dorent R, Wechsler B, et al. Pacemaker infective endocarditis. Am J Cardiol. 1998;82:480-4.
148. Victor F, De Place C, Camus C, Le Breton H, Leclercq C, Pavin D, et al. Pacemaker lead infection: echocardiographic features, management, and outcome. Heart. 1999;81:82-7.
149. Massoure PL, Reuter S, Lafitte S, Laborderie J, Bordachard P, Clementy J, et al. Pacemaker endocarditis: clinical features and management of 60 consecutive cases. Pacing Clin Electrophysiol. 2007;30:12-9.
150. Del Río A, Anguera I, Miró JM, Mont L, Fowler VG Jr, Azqueta M, et al. Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. Chest. 2003;124:1451-9.
151. Capdevila JA, Almirante B. Infecciones endovasculares en el anciano. En: Sabriá M, Carrasco I, coordinadores. Infecciones en el anciano. Barcelona: Ediciones Experiencia; 2006. p. 99-115.
152. Camus C, Leport C, Raffi F, Michelet C, Cartier F, Vilde JL. Sustained bacteremia in 26 patients with a permanent endocardial pacemaker: assessment of wire removal. Clin Infect Dis. 1993;17:46-55.
153. Ruttmann E, Hangler HB, Kilo J, Höfer D, Müller LC, Hintringer F, et al. Transvenous pacemaker lead removal is safe and effective even in large vegetations: an analysis of 53 cases of pacemaker lead endocarditis. Pacing Clin Electrophysiol. 2006;29:231-6.
154. Da Costa A, Kirkorian G, Cucherat M, Delahaye F, Chevalier P, Cerisier A, et al. Antibiotic prophylaxis for permanent pacemaker implantation: a meta-analysis. Circulation. 1998;97:1796-801.
155. Bertaglia E, Zerbo F, Zardo S, Barzan D, Zoppo F, Pascotto P. Antibiotic prophylaxis with a single dose of cefazolin during pacemaker implantation: incidence of long-term infective complications. Pacing Clin Electrophysiol. 2006;29:29-33.